Etoricoxib with L-dopa for Parkinson's disease
Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
This trial will test whether adding etoricoxib to usual Parkinson's treatment lowers inflammation markers and helps adults with Parkinson's disease.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 50 Years to 70 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Al Mansurah) |
| Trial ID | NCT07370532 on ClinicalTrials.gov |
What this trial studies
This is a Phase 2, single-site interventional trial testing the COX-2 inhibitor etoricoxib alongside L-dopa in adults diagnosed with Parkinson's disease. The study will enroll patients meeting clinical Parkinson's criteria (using the UPDRS) and excludes pregnant or breastfeeding people, those with significant liver or kidney problems, current users of other anti-inflammatory drugs, and people with substance abuse or allergies to the study medications. Outcomes likely include changes in inflammatory biomarkers such as HMGB1 and receptor pathways (TLR4/RAGE) and clinical Parkinson's measures. The trial is being conducted at Mansoura University in Al Mansurah, Egypt.
Who should consider this trial
Good fit: Adults (age 18 or older) with a clinical diagnosis of Parkinson's disease by UPDRS who are not pregnant or breastfeeding and who do not have significant liver or kidney impairment may be eligible.
Not a fit: People who are pregnant or breastfeeding, have significant liver or kidney dysfunction, are using other anti-inflammatory drugs, have drug allergies to the study medications, or have active substance abuse are unlikely to qualify or benefit from participation.
Why it matters
Potential benefit: If successful, the treatment could reduce neuroinflammation and potentially improve symptoms or slow progression in some people with Parkinson's disease.
How similar studies have performed: Preclinical work and small clinical studies of COX-2 inhibitors suggest possible anti-inflammatory effects, but clear clinical benefit in Parkinson's disease remains unproven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * Both male and female will be included. * Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale. Exclusion Criteria: * Breast feeding * Patients with significant liver and kidney function abnormalities. * Alcohol and / or drug abusers. * Patients with known allergy to the study medications * Pregnant women and women with planned pregnancy. * Patients who are currently using other anti-inflammatory drugs.
Where this trial is running
Al Mansurah
- Mansoura University — Al Mansurah, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.